NICE’s five-year strategy sets a ‘positive vision for the future’
20th April 2021
The pharma industry has responded to the National Institute for Health and Care Excellence’s (NICE) new five-year strategy, announced yesterday.
In response to NICE’s new guideline recommendations, Richard Torbett, chief executive of the Association of the British Pharmaceutical Industry (ABPI) commented: “Pharmaceutical companies are working on thousands of exciting new medicines and treatments, from rare disease gene therapies to mRNA vaccines for cancer.”
He added: “Today’s strategy sets out a positive vision for the future of NICE; one which will see it evolve with the science that makes these breakthroughs possible and build on its international reputation for producing evidence-based guidance.”
United Kingdom: Post-Brexit batch testing: Extended recognition by the UK
globalcompliancenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalcompliancenews.com Daily Mail and Mail on Sunday newspapers.
UK government sets out bold vision for the future of clinical research delivery
gov.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gov.uk Daily Mail and Mail on Sunday newspapers.
Thousands of activists across the world demanded a People’s Vaccine as part of the global day of action on the first anniversary of the World Health Organization declaring coronavirus a pandemic.
Together with the People’s Vaccine Alliance, we helped to mobilise and co-ordinate organisations, networks and activists across to the world to demand end to vaccine apartheid. While vaccines are being rolled out in rich countries, the global south could be waiting up to 2023 for widespread vaccination.
We are calling for equitable access to Covid-19 vaccinations for everyone, everywhere, but pharmaceutical companies and rich countries’ governments are defending corporate profits by blocking a proposal to suspend patent rules that would help the ramp up production so there are enough vaccines doses to meet global demand.